PCR for Aspergillus Fumigatus in Blood and Bronchoalveolar Lavage Fluid for Monitoring Cases of Invasive Aspergillosis: What is Its Prognostic Value
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Death rate at day 30 in patients with a positive follow-up PCR (blood or bronchoalveolar lavage)
研究概览
简要总结
Aspergillus fumigatus PCR is currently used in conjunction with serum galactomannan to support the diagnosis of invasive aspergillosis or for monitoring at-risk patients not receiving antifungal prophylaxis. A positive result and a high titer are thought to be associated with the advanced stage of the disease and the fungal load. However, there is limited data on this subject, and no study has primarily focused on the variation of PCR levels during treatment and its potential correlation with treatment efficacy.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 18 years or older
- •Positive Aspergillus fumigatus PCR on serum or bronchoalveolar lavage fluid at diagnosis, performed at the Strasbourg University Hospital between January 1, 2017, and December 31, 2024.
排除标准
- •No subsequent Aspergillus fumigatus PCR (>24h)
- •No diagnosis of probable or proven invasive aspergillosis (EORTC/MSGERC 2020 criteria)
- •Effective antifungal treatment against Aspergillus initiated before the first PCR
- •Death <72h after starting antifungal treatment
结局指标
主要结局
Death rate at day 30 in patients with a positive follow-up PCR (blood or bronchoalveolar lavage)
时间窗: Day 30 post-antifungal treatment
Death rate at day 30 in patients with a positive follow-up PCR (blood or bronchoalveolar lavage) after the start of treatment
次要结局
未报告次要终点